A multicenter, open, long term safety study of 52 weeks treatment with vildagliptin (100 mg qd) in patients with type 2 diabetes (extension study of study CLAF237A1303)
Phase of Trial: Phase III
Latest Information Update: 20 May 2016
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 24 Mar 2008 Status changed from in progress to completed on clinicaltrials.gov.
- 25 Jun 2007 New trial record.